Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 274, Issue 1-2, Pages 185-191Publisher
ELSEVIER
DOI: 10.1016/j.jneuroim.2014.07.001
Keywords
Neuromyelitis optica; Complement; Aquaporin-4 IgG; C1q antibodies
Categories
Funding
- Grant Agency of the Charles University [GAUK 132010]
- Czech Ministries of Education and Health [PRVOUK-P26/ LF1/4, NT13237-4/2012]
- National Health Service National Specialised Commissioning Group for Neuromyelitis Optica
- National Institute for Health Research Oxford Biomedical Research Centre
- Guarantors of Brain, Fond Mobility of the Charles University and Euroimmun
- Swiss National Foundation [310030_134900/1]
- Swiss National Science Foundation (SNF) [310030_134900] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
The role of complement has been demonstrated in experimental models of neuromyelitis optics (NMO), however, only few studies have analysed complement components longitudinally in NMO patients. We measured serum or plasma concentrations of anti-C1q antibodies and complement split products C3a and C4a and soluble C5b-9 in patients with NMO, multiple sclerosis and healthy controls. NMO patients had higher levels of C3a and anti-C1q antibodies than healthy controls. C3a levels correlated with disease activity, neurological disability and aquaporin-4 IgG in NMO patients suggesting a role of the alternative pathway of complement in the pathogenesis of NMO and supporting the strategy of therapeutic complement inhibition. (C) 2014 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
